Sage Journals: Discover world-class research

Open access

Research article

First published 2026

Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls

Silvia Park, Suein Choi, Seunghoon Han [...]

Therapeutic Advances in Hematology

Open access

Review article

First published 2023

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

Robert Briski, Guillermo Garcia-Manero, Hagop Kantarjian [...]

Therapeutic Advances in Hematology

Free access

Research article

First published 2012-1

Novel Insights into the Molecular Mechanism of Action of DNA Hypomethylating Agents

Jharna Datta, Kalpana Ghoshal, Tasneem Motiwala [...]

Genes & Cancer

Free access

Letter

First published 2011-9

Decitabine for Acute Myeloid Leukemia in a Patient Undergoing Hemodialysis

T.V. Kourelis, M.N. Moustakakis, R. Silk [...]

European Journal of Inflammation

Open access

Review article

First published 2024

Clinical activity,pharmacokinetics,and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review

Ryan Haumschild, Julie Kennerly-Shah, Lisa Barbarotta [...]

Journal of Oncology Pharmacy Practice

Open access

Brief report

First published 2013-06

Human Skin Keratinocytes Can Be Reprogrammed to Express Neuronal Genes and Proteins After a Single Treatment with Decitabine

Jackie R. Bickenbach, Ann Tomanek-Chalkley, Susan Wiechert [...]

BioResearch Open Access

Open access

Research article

First published 2017

DNMT3a contributes to the development and maintenance of bone cancer pain by silencing Kv1.2 expression in spinal cord dorsal horn

Xue-Rong Miao, Long-Chang Fan, Shaogen Wu [...]

Molecular Pain

Search results

Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

Novel Insights into the Molecular Mechanism of Action of DNA Hypomethylating Agents

Decitabine for Acute Myeloid Leukemia in a Patient Undergoing Hemodialysis

Clinical activity,pharmacokinetics,and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review

Human Skin Keratinocytes Can Be Reprogrammed to Express Neuronal Genes and Proteins After a Single Treatment with Decitabine

DNMT3a contributes to the development and maintenance of bone cancer pain by silencing Kv1.2 expression in spinal cord dorsal horn